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We read with interest the viewpoint on the use of the “fibrosis benefit index” as a 
surrogate outcome in registration trials for non-alcoholic steatohepatitis 
(NASH)1. Effective NASH treatments are indeed an unmet clinical need; given the 
relative long natural history of NASH, validated surrogate endpoints are 
required. Primary endpoints in current phase IIb or III trials include the 
resolution of NASH without worsening of fibrosis or the improvement of fibrosis 
without resolution of NASH.  
The resolution (or improvement) of NASH is a problematic endpoint, as it has 
unacceptably high inter- and intra-observer variability and more importantly 
has consistently failed to correlate with clinical outcomes2. Therefore, 
investigational medicinal products in trials that are using this endpoint are in 
peril of a “false positive” or “false negative” signal for further development or 
licensing.  
The second surrogate endpoint, improvement in fibrosis, is assessed through a 
5-point semi-quantitative scoring system that takes into account both 
architecture and fibrosis. Although each stage has an assigned number, there is 
no quantitative relation between stages, i.e. stage 2 doesn’t mean twice as much 
fibrosis as stage 13. Importantly, the progression (or regression) of fibrosis is not 
linear and varies depending on the severity of liver disease. The main issue is 
that progression or regression through stages might not be observed in the 
relative short duration of trials. The proposed benefit index accentuates this 
problem, as it requires either resolution of fibrosis or progression to cirrhosis. 
For patients with advanced fibrosis, resolution of fibrosis is a contentious issue, 
while for those with lesser stages progression to cirrhosis might take more than 
a decade.  
The fibrosis benefit index will only improve the assessment of treatment 
outcome only if fibrosis is precisely assessed with an objective quantitative 
methodology. We therefore propose the use of quantitative fibrosis assessment 
using collagen proportionate area (CPA) as a surrogate endpoint and the 
abandoning of the steatohepatitis component. CPA is a pure measure of fibrosis, 
can sub-classify cirrhosis and correlates with both HVPG and clinical outcomes4. 
More importantly, we recently validated CPA in NASH; we showed that it reliably 
measures peri-cellular fibrosis in pre-cirrhotic NASH and is an independent 
predictor of clinical outcomes5. CPA has excellent inter- and intra-observer 
variability and is not time consuming. More importantly, it can capture 
meaningful changes in fibrosis in a shorter timeframe than progression through 
semi-quantitative stages and thus provide an accelerated pathway for drug 
development and registration. 
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